Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Non Operating Income (2022 - 2025)

BioXcel Therapeutics has reported Non Operating Income over the past 4 years, most recently at $1.8 million for Q4 2025.

  • Quarterly results put Non Operating Income at $1.8 million for Q4 2025, down 45.06% from a year ago — trailing twelve months through Dec 2025 was -$3.5 million (down 117.44% YoY), and the annual figure for FY2025 was -$3.5 million, down 117.44%.
  • Non Operating Income for Q4 2025 was $1.8 million at BioXcel Therapeutics, up from -$12.5 million in the prior quarter.
  • Over the last five years, Non Operating Income for BTAI hit a ceiling of $12.0 million in Q2 2024 and a floor of -$12.5 million in Q3 2025.
  • Median Non Operating Income over the past 4 years was $322500.0 (2023), compared with a mean of $1.2 million.
  • Biggest five-year swings in Non Operating Income: skyrocketed 96440.0% in 2024 and later tumbled 360.45% in 2025.
  • BioXcel Therapeutics' Non Operating Income stood at -$480000.0 in 2022, then skyrocketed by 122.5% to $108000.0 in 2023, then surged by 2953.7% to $3.3 million in 2024, then tumbled by 45.06% to $1.8 million in 2025.
  • The last three reported values for Non Operating Income were $1.8 million (Q4 2025), -$12.5 million (Q3 2025), and $657000.0 (Q2 2025) per Business Quant data.